INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<table>
<thead>
<tr>
<th>(51) International Patent Classification 4 :</th>
<th>A61K 7/48, 47/00, A61L 15/03</th>
</tr>
</thead>
<tbody>
<tr>
<td>(11) International Publication Number:</td>
<td>WO 87/ 01935</td>
</tr>
<tr>
<td>(43) International Publication Date:</td>
<td>9 April 1987 (09.04.87)</td>
</tr>
<tr>
<td>(21) International Application Number:</td>
<td>PCT/US66/02052</td>
</tr>
<tr>
<td>(22) International Filing Date:</td>
<td>1 October 1986 (01.10.86)</td>
</tr>
<tr>
<td>(31) Priority Application Number:</td>
<td>783,621</td>
</tr>
<tr>
<td>(32) Priority Date:</td>
<td>3 October 1985 (03.10.85)</td>
</tr>
<tr>
<td>(33) Priority Country:</td>
<td>US</td>
</tr>
</tbody>
</table>

Published

*With international search report.*


(81) Designated States: AT (European patent), BE (European patent), CH (European patent), DE (European patent), FR (European patent), GB (European patent), IT (European patent), JP, LU (European patent), NL (European patent), SE (European patent).

(54) Title: TRANSDERMAL AND SYSTEMIC PREPARATION AND METHOD

(57) Abstract

Physiologically active azepines, pyrrolidines and piperidines for enhancing penetration of physiologically active agents.
FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>AT</td>
<td>Austria</td>
<td>FR</td>
<td>France</td>
<td>ML</td>
<td>Mali</td>
</tr>
<tr>
<td>AU</td>
<td>Australia</td>
<td>GA</td>
<td>Gabon</td>
<td>MR</td>
<td>Mauritania</td>
</tr>
<tr>
<td>BB</td>
<td>Barbados</td>
<td>GB</td>
<td>United Kingdom</td>
<td>MW</td>
<td>Malawi</td>
</tr>
<tr>
<td>BE</td>
<td>Belgium</td>
<td>HU</td>
<td>Hungary</td>
<td>NL</td>
<td>Netherlands</td>
</tr>
<tr>
<td>BG</td>
<td>Bulgaria</td>
<td>IT</td>
<td>Italy</td>
<td>NO</td>
<td>Norway</td>
</tr>
<tr>
<td>BJ</td>
<td>Benin</td>
<td>JP</td>
<td>Japan</td>
<td>RO</td>
<td>Romania</td>
</tr>
<tr>
<td>BR</td>
<td>Brazil</td>
<td>KP</td>
<td>Democratic People's Republic of Korea</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CF</td>
<td>Central African Republic</td>
<td>KR</td>
<td>Republic of Korea</td>
<td>SD</td>
<td>Sudan</td>
</tr>
<tr>
<td>CG</td>
<td>Congo</td>
<td>LI</td>
<td>Liechtenstein</td>
<td>SE</td>
<td>Sweden</td>
</tr>
<tr>
<td>CH</td>
<td>Switzerland</td>
<td>LK</td>
<td>Sri Lanka</td>
<td>SN</td>
<td>Senegal</td>
</tr>
<tr>
<td>CM</td>
<td>Cameroon</td>
<td>LU</td>
<td>Luxembourg</td>
<td>SU</td>
<td>Soviet Union</td>
</tr>
<tr>
<td>DE</td>
<td>Germany, Federal Republic of</td>
<td>MC</td>
<td>Monaco</td>
<td>TD</td>
<td>Chad</td>
</tr>
<tr>
<td>DK</td>
<td>Denmark</td>
<td>MG</td>
<td>Madagascar</td>
<td>TG</td>
<td>Togo</td>
</tr>
<tr>
<td>FI</td>
<td>Finland</td>
<td></td>
<td></td>
<td>US</td>
<td>United States of America</td>
</tr>
</tbody>
</table>
TRANSDERMAL AND SYSTEMIC PREPARATION AND METHOD

Background of the Invention

Many physiologically active agents are best applied topically to obtain desirable results. Topical application, in the form of creams, lotions, gel, solutions, et., largely avoids side effects of the agents and permits high level concentrations of the agents.

Some therapeutics drugs may also be administered for systemic use through the skin or other body membranes including intranasal and intravaginal application of humans and other animals, utilizing a transdermal device or formulated in a suppository or aerosol spray. For some years, pharmaceutical researchers have sought an effective means of introducing drugs into the bloodstream by applying them to the unbroken skin. Among other advantages, such administration can provide a comfortable, convenient and safe way of giving many drugs now taken orally or infused into veins or injected intramuscularly.

Using skin as the portal for drug entry offers unique potential, because of transdermal delivery permits close control over drug absorption. For example, it avoids factors that can cause unpredictable absorption from gastrointestinal tract, including: changes in acidity, motility, and food content. It also avoids initial metabolism of the drug by the liver, known as the first pass effect. Thus, controlled drug entry through skin can achieve a high degree of control over blood concentrations of drug.

Close control over drug concentration in blood can translate readily into safer and more comfortable treatment. When a drug's adverse effects occur at higher concentrations than its beneficial ones, rate control can maintain the concentration that evoke only - or principally the drug's desired actions. This ability to lessen undesired drug actions can greatly reduce the toxicity hazards that now restrict or prevent the use of many valuable agents.
many valuable agents.

Transdermal delivery particularly benefits patients with chronic disease. Many such patients have difficulty following regimens requiring several doses daily of medications that repeatedly cause unpleasant symptoms. They find the same drugs much more acceptable when administered in transdermal systems that require application infrequently - in some cases, only once or twice weekly - and reduce adverse effects.

Transdermal delivery is feasible for drugs effective in amounts that can pass though the skin area and that are substantially free of localized irritating or allergic effects. While these limitations may exclude some agents, many others remain eligible for transdermal delivery. Moreover, their numbers will expand as pharmaceutical agents of greater potency are developed. Particularly suitable for transdermal delivery are potent drugs with only a narrow spread between their toxic and safe blood concentrations, those having gastrointestinal absorption problems, those susceptible to a higher first pass liver metabolism or those requiring frequent dosing in oral or injectable form.

Transdermal therapy permits much wider use of natural substances such as hormones. Often the survival times of these substances in the body are so short that they would have to be taken many times daily in ordinary dosage forms. Continuous transdermal delivery provides a practical way of giving them, and one that can mimic the body's own patterns of secretion.

At present, controlled transdermal therapy appears feasible for many drugs used for a wide variety of ailments including, but not limited to, circulatory problems, hormone deficiency, respiratory ailments, and pain relief.

Percutaneous administration can have the advantage of permitting continuous administration of drug
to the circulation over prolonged period of time to obtain a uniform delivery rate and blood level of drug. Commencement and termination of drug therapy are initiated by the application and removal of the dosing devices from the skin. Uncertainties of administration through the gastrointestinal tract and the inconvenience of administration by injection are eliminated. Since a high concentration of drug never enters the body, problems of pulse entry are overcome and metabolic half-life is not a factor of controlling importance.

The greatest problems in applying physiologically active agents topically or transdermally is that the skin is an effective barrier to penetration. The epidermis of the skin has an exterior layer of dead cells called the stratum corneum which is tightly compacted and oily and which provides an effective barrier against gaseous, solid or liquid chemical agents, whether used alone or in water or in oil solutions. If a physiologically active agent penetrates the stratus corneum, it can readily pass through the basal layer of the epidermis and into the dermis.

Although the effectiveness of the stratum corneum as a barrier provides great protection, it also frustrates efforts to apply beneficial agents directly to local areas of the body. The inability of physiologically active agents to penetrate the stratum corneum prevents their effective use of treating such conditions as inflammation, acne, psoriasis, herpes simplex, eczema, infections caused by fungi, viruses and other microorganisms, or other disorders or conditions of the skin or mucous membranes, or of conditions beneath the exterior surface of the skin or mucous membranes. The stratum corneum also prevents the skin from absorbing and retaining cosmetic-type materials such as sunscreens, perfumes, mosquito repellants and the like.

Physiologically active agents may be applied to
the locally affected parts of the body in the form of a solution, cream, lotion or gel utilizing the vehicle system described herein. These agents may also be delivered for systemic use utilizing the vehicle system in a transdermal patch. Vehicles such as USP cold cream, ethanol and various ointments, oils, solvents and emulsions have been used heretofore to apply physiologically active ingredients locally. Most such vehicles are not effective to carry significant amounts of physiologically active agents into and through the skin. One such vehicle is dimethyl sulfoxide, which is described in U.S. Patent No. 3,551,554.

My previous inventions disclosed in U.S. Patent Nos. 3,989,816; 3,991,203; 4,122,170; 4,316,893; 4,415,563; 4,423,040; 4,424,210; 4,444,762 describe a method for enhancing the topical administration of physiologically active agents by combining such an agent with an effective amount of a penetration enhancer and applying the combination topically to humans or animals, in the form of solution, cream, gels, lotions etc. This prior art discloses N-alkyl substituted cyclic lactams as penetration enhancers.

My related U.S. Patent 4,405,616, describes a method for administering systemically active agents through the skin or other body membranes of humans and animals, utilizing a transdermal device or formulation containing an effective amount of a suitable membrane penetration enhancer selected from the disclosed N-alkyl substituted cyclic lactams.

Penetration enhancers for enhancing systemic administration of therapeutic agents transdermally disclosed in the art include dodecyl pyrrolidone, dimethyl lauramide and dimethyl sulfoxide. The prior art states that these agents may be used prior to or concurrently with administration of the active agent, e.g. see U.S. Patent Nos. 4,031,894; 3,996,934 and 3,921,636.
SUMMARY OF THE INVENTION

The invention relates to compositions for carrying physiologically active agents through body membranes such as skin and for retaining these agents in body tissues and further relates to a method of administering systemically active agents through the skin or other body membranes of humans and animals, utilizing a transdermal device or formulation, containing an effective, non-toxic amount of a membrane penetration enhancer having the structural formula I:

\[
\begin{align*}
&\text{(CH}_2\text{)}_m \quad \text{N-C-R} \\
&\text{(R')}_n
\end{align*}
\]

where, R is an alkyl group with from 1 to 19 carbon atoms;

wherein \( m = 4, 5 \) and 6
\( n = 0 - 4 \)
and \( \text{R'} = \text{H or COOH} \)

In one preferred embodiment, R is 6 to 19
In another preferred embodiment of

\[
\begin{align*}
&\text{(CH}_2\text{)}_m - \quad \text{N-C-R} \\
&\text{(R')}_n
\end{align*}
\]

where \( m \) is 4 to 6, \( R \) is 1 - 19, \( \text{R'} \) is \( \text{H} \) and \( n \) is 1.

The preferred compound is 1-dodecanoylhexahydro-1H-azepine.

In another preferred embodiment,
m is 4 to 6, R is 1 to 19, R' is COOH and n is 1. The preferred compounds are in which m is 4 and 5, R' is 2-COOH, and R is 11, for example, 1-dodecanoyl-2-carboxypyrrolidine

5 and 1-dodecanoyl-2-carboxypiperidine.

It has been found that the physiologically active agents are carried through body membranes by the claimed penetration enhancers and are retained in the body tissue when applied topically in form of a cream, gel or lotion or absorbed systemically when applied in the form of a transdermal device or formulation, for example, as a rectal or vaginal suppository, as a nasal spray or when incorporated in a vaginal sponge.

15  **DETAILED DESCRIPTION OF THE INVENTION**

Typical examples of compounds included in the foregoing formula I of this invention are the following:

1) 1-butyrylpyrrolidine
2) 1-pentanoylpyrrolidine
3) 1-hexanoylpyrrolidine
4) 1-octanoylpyrrolidine
5) 1-nonanoylpyrrolidine
6) 1-decanoylpyrrolidine
7) 1-dodecanoylpyrrolidine
8) 1-tetradecanoylpyrrolidine
9) 1-hexadecanoylpyrrolidine
10) 1-pentanoylpiperidine
11) 1-hexanoylpiperidine
12) 1-heptanoylpiperidine
13) 1-octanoylpiperidine
14) 1-nonanoylpiperidine
15) 1-decanoylpiperidine
16) 1-dodecanoylpiperidine
17) 1-tetradecanoylpiperidine
18) 1-hexadecanoylpiperidine
19) 1-butyrylhexahydro-1H-azepine
20) 1-pentanoylhexahydro-1H-azepine
21) 1-hexanoylhexahydro-1H-azepine
22) 1-heptanoylhexahydro-1H-azepine
23) 1-octanoylhexahydro-1H-azepine
24) 1-nonanoylhexahydro-1H-azepine
25) 1-decanoylhexahydro-1H-azepine
26) 1-dodecanoylhexahydro-1H-azepine
27) 1-tetradecanoylhexahydro-1H-azepine
28) 1-hexadecanoylhexahydro-1H-azepine
29) 1-butyryl-2-carboxypyrrolidine
30) 1-hexanoyl-2-carboxypyrrolidine
31) 1-octanoyl-2-carboxypyrrolidine
32) 1-decanoyl-2-carboxypyrrolidine
33) 1-dodecanoyl-2-carboxypyrrolidine
34) 1-tetradecanoyl-2-carboxypyrrolidine
35) 1-hexadecanoyl-2-carboxypyrrolidine
36) 1-hexanoyl-2-carboxypiperidine
37) 1-octanoyl-2-carboxypiperidine
38) 1-decanoyl-2-carboxypiperidine
39) 1-dodecanoyl-2-carboxypiperidine
40) 1-tetradecanoyl-2-carboxypiperidine
41) 1-hexadecanoyl-2-carboxypiperidine
42) 1-hexanoyl-3-carboxypiperidine
43) 1-octanoyl-3-carboxypiperidine
44) 1-decanoyl-3-carboxypiperidine
45) 1-dodecanoyl-3-carboxypiperidine
46) 1-tetradecanoyl-3-carboxypiperidine
47) 1-hexadecanoyl-3-carboxypiperidine
48) 1-hexanoyl-4-carboxypiperidine
49) 1-octanoyl-4-carboxypiperidine
50) 1-decanoyl-4-carboxypiperidine
51) 1-dodecanoyl-4-carboxypiperidine
52) 1-tetradecanoyl-4-carboxypiperidine
53) 1-hexadecanoyl-4-carboxypiperidine

The compounds covered by the general formula I may be prepared by any of the processes known for the preparation of acid amides. For example, (1) a carboxylic acid, R-COOH, is made to react directly with an amine of the formula II,

\[ \text{(CH}_2\text{)}_m \text{NH} \text{(R')}_n \]

(II)

(wherein m, n, R and R' are as defined above) in the absence or presence of such dehydrating agents as a disubstituted carbodiimide compound, carbonyl diimidazole,
p-toluenesulphonic acid, p-toluenesulphonyl chloride or acetic anhydride [Starkov et. al., Chem. Abstr., 72, 31583 (1970)], in an aqueous or organic solvent, (2) a carboxylic acid halide, R-CO-X (where X is Cl or Br), prepared from a carboxylic acid, R-COOH, and the resulting acid halide is treated with at least an equimolar amount of the amine II, in the presence of a basic condensing agent [Alexander et. al., J. Econ. Entomol., 56, 58 (1963); Kukuchi et. al., Biochim. Biophys. Acta 744, 180 (1963)], (3) a lower alkyl ester of a carboxylic acid, R-COOR' (where R' is lower alkyl group with 1-3 carbons) is made to react directly with the amine, II, in the presence or absence of a solvent and condensing agent, (4) a mixed acid anhydride of a carboxylic acid of the formula,

\[ R-C-O-C-R_2 \]

(wherewith R is as defined above and R_2 is an alkyl or haloalkyl radical having 1-20 carbon atoms) is made to react with the amine, II, in the presence of a basic condensing catalyst, (5) amine of formula II is treated with a carboxylic acid in the presence of trimethylamine-borane in an aromatic hydrocarbon solvent, such as xylene [Trapani et. al., Synthesis, 1013 (1983)] or (6) transamidation of formylpiperidine and formylhexamethylenemine with a carboxylic acid over 220 C [Naumov et. al., Chem. Abstr., 76, 85678u (1972)].

The compounds of the present invention may be used as penetration enhancers in the same manner as described in my U.S. Patents 3,989,816; 3,991,203; 4,415,563; 4,122,170; 4,316,893; 4,423,040; 4,424,210 and 4,444,762, which are hereby incorporated by reference.

The compounds of the present inventions are useful as penetration enhancers for a wide range of physiologically active agents and the compositions
disclosed herein are useful for topical and transdermal therapeutic effect of these agents. Typically systemically active agents which may be delivered transdermally are therapeutic agents which are sufficiently potent such that they can be delivered through the skin or other membranes to the bloodstream in sufficient quantities to produce the desired therapeutic effect. In general this includes agents in all of the major therapeutic areas including, but not limited to, anti-infectives, such as antibiotics and antiviral agents, analgesics, anorexics, anthelmintics, antiarthritics, antiasthma agents, anticoagulants, antidepressants, antidiabetic agents, antimigraine preparations, anticonvulsants, antineoplastic agents, antiparkinsonism drugs, antipsychotics, antipyretics, antispasmodics, including gastrointestinal and urinary; anticholinergics, sympathomimetics, xanthine derivatives, cardiovascular preparations including calcium channel blockers, beta-blockers, antiarrhythmic, antihypertensives, diuretics, vasodilators including general, coronary, peripheral and cerebral; central nervous system stimulants, cough and cold preparations, decongestants, diagnostics, hormones, hypnotics, immunosuppressives, muscle relaxants, parasympathomimetics, parasympathomimetics, sedatives and tranquilizers.

For topical applications the agents include antibiotics, fungistatic and fungicidal agents, corticosteroids, agents, antiemetics, antipruritic agents, vasodilators, bronchodilators, expectorants, analgesics, sunscreen compounds, collagen softening agents and other similar compounds. Cosmetic agents, hair and skin dyes, natural and synthetic hormones, perfumes, insect repellents, diagnostic agents and other such compounds may also be advantageously formulated with these penetration enhancers.

Some of these penetration enhancers can also be
used by themselves as moisturizers in cosmetic formulations. Moreover, these penetration enhancers are useful in agriculture in the application of fertilizers, hormones, growth factors including micronutrients, insecticides, molluscicides, arachicides, nematocides, rodenticides, herbicides, and other pesticides to plants, animals and pests. These penetration enhancers are also useful for penetration of micronutrients in seeds for enhanced plant growth.

Of course, the appropriate dosage levels of all the physiologically active agents, without conjoint use of the penetration enhancing compounds of formula I, are known to those of ordinary skill in the art. These conventional dosage levels correspond to the upper range of dosage levels for compositions including a physiologically active agent and a compound of formula I as a penetration enhancer. However, because the delivery of the active agent is enhanced by compounds of the present invention, dosage levels significantly lower than conventional dosage levels may be used with success. Systemically active agents are used in amounts calculated to achieve and maintain therapeutic blood levels in a human or other animal over the period of time desired. (The term "animal" as used here encompasses humans as well as other animals, including particularly pets and other domestic animals.) These amounts vary with the potency of each systemically active substance, the amount required for the desired therapeutic or other effect, the rate of elimination or breakdown of the substance by the body once it has entered the bloodstream and the amount of penetration enhancer in the formulation. In accordance with conventional prudent formulating practices, a dosage near the lower end of the useful range of a particular agent is usually employed initially and the dosage increased or decreased as indicated from the observed response, as in the routine procedure of the physician.
The present invention contemplates compositions of compounds of formula I, together with physiologically active agents from 0.05% to 100% of conventional dosage levels. The amount of carboxylic acid amide which may be used in the present invention is an effective, non-toxic amount for enhancing percutaneous absorption. Generally, for topical use the amount ranges between 0.01 to about 10 and preferably about 0.1 to 5 percent by weight of the composition. For transdermal enhancement of systemic agents, the amount of penetration enhancer which may be used in the invention varies from about 1 to 100 percent although adequate enhancement of penetration is generally found to occur in the range of about 1 to 30 percent by weight of the formulation to be delivered. For transdermal use, the penetration enhancers disclosed herein may be used in combination with the active agent or may be used separately as a pre-treatment of the skin or other body membranes through which the active agent is intended to be delivered.

Dosage forms for application to the skin or other membranes of humans and animals include creams, lotions, gels, ointments, suppositories, sprays, aerosols, buccal and sublingual tablets and any one of a variety of transdermal devices for use in the continuous administration of systemically active drugs by absorption through the skin, oral mucosa or other membranes, see for example, one or more of U.S. Patent Nos. 3,598,122; 3,598,123; 3,731,683; 3,742,951; 3,814,097; 3,921,636; 3,972,995; 3,993,072; 3,993,073; 3,996,934; 4,031,894; 4,060,084; 4,069,307; 4,201,211; 4,230,105; 4,292,299 and 4,292,303. U.S. Patent No. 4,077,407 and the foregoing patents also disclose a variety of specific systemically active agents which may also be useful as in transdermal delivery, which disclosures are hereby incorporated herein by this reference.

Typical inert carriers which may be included in
the foregoing dosage forms include conventional formulating materials, such as, for example, water, ethanalamol, 2-propanol (isopropyl alcohol), 1,2-propanediol (propylene glycol), 1,3-butanediol, 1,2,3-propanetriol (glycerol), propanone (acetone), butanone (methyl ethyl ketone), freons, polyvinyl pyrrolidone, fragrances, gel producing materials such as "Carbopol", stearyl alcohol, stearic acid, spermaceti, sorbitan monooleate, sorbitol, "polysorbates", "Tweens", methyl cellulose etc.

The examples which follow illustrate the penetration enhancers and the compositions of the present invention.

**Example 1**

Preparation of 1-hexanoylpyrrolidine

Hexanoyl chloride (13.46 g, 0.1 M) was added gradually to a cooled, stirred solution of pyrrolidine (7.25 g, 0.1 M) in 200 ml of benzene and dry pyridine (7.91 g, 0.1 M). Two hours after the addition water was added. The organic layer was washed successively with 5% aqueous hydrochloric acid, saturated sodium bicarbonate solution, and saturated sodium chloride solution. The organic layer was dried over anhydrous sodium sulfate, filtered and concentrated. Distillation of the residue gave 13.52 g (80%) of a colorless oil, b.p. 98-100 / 7 mm.

The following compounds were prepared analogously by substituting equimolar amount of the corresponding carboxylic acid chlorides:

- 1-octanoylpyrrolidine 83% 110-115 / 0.3 mm
- 1-nonanoylpyrrolidine 76% 137 / 0.5 mm
- 1-tetradecanoylpyrrolidine 75% 177-180 / 0.3 mm
- 1-hexadecanoylpyrrolidine 70% 200-205 / 1 mm

The following compounds are prepared analogously by substituting equimolar amounts of the corresponding carboxylic acid chlorides:

- 1-decanoylpyrrolidine
- 1-dodecanoylpyrrolidine
EXAMPLE 2

Preparation of 1-dodecanoylpiriderine

In a manner similar to that described in Example 1, dodecanoyl chloride (21.88 g, 0.1M) was treated with piperidine (8.52 g, 0.1M). Work up and distillation gave 16.55 g (62%) of the product, b.p. 185 / 2 mm.

The following compounds were prepared analogously by substituting equimolar amount of the corresponding carboxylic acid chlorides:

<table>
<thead>
<tr>
<th>Compound</th>
<th>Yield %</th>
<th>B.P.</th>
</tr>
</thead>
<tbody>
<tr>
<td>1-pentanoylpiriderine</td>
<td>70%</td>
<td>122-125 / 10 mm</td>
</tr>
<tr>
<td>1-hexanoylpiriderine</td>
<td>71%</td>
<td>101-102 / 0.5 mm</td>
</tr>
<tr>
<td>1-heptanoylpiriderine</td>
<td>70%</td>
<td>158-162 / 12 mm</td>
</tr>
<tr>
<td>1-octanoylpiriderine</td>
<td>69%</td>
<td>101-102 / 0.3 mm</td>
</tr>
<tr>
<td>1-nonanoylpiriderine</td>
<td>67%</td>
<td>105 / 0.1 mm</td>
</tr>
<tr>
<td>1-decanoylpiriderine</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1-tetradecanoylpiriderine</td>
<td>63%</td>
<td>174 / 0.5 mm</td>
</tr>
<tr>
<td>1-hexadecanoylpiriderine</td>
<td>57%</td>
<td>182 / 0.3 mm</td>
</tr>
</tbody>
</table>

Example 3

Preparation of 1-octanoylhexahydro-1H-azepine

In a manner similar to that described in Example 1, octanoyl chloride (16.26 g, 0.1M) was treated with hexahydro-1H-azepine (9.92 g, 0.1M). Work up and distillation of the residue gave 15.3 g (68%) of product, b.p. 122 / 0.8 mm.

The following compounds were prepared analogously by substituting equimolar amount of the corresponding carboxylic acid chlorides:

<table>
<thead>
<tr>
<th>Compound</th>
<th>Yield %</th>
<th>B.P.</th>
</tr>
</thead>
<tbody>
<tr>
<td>1-hexanoylhexahydro-1H-azepine</td>
<td>66%</td>
<td>112 / 0.8 mm</td>
</tr>
<tr>
<td>1-nonanoylhexahydro-1H-azepine</td>
<td>84%</td>
<td>123-124 / 0.02 mm</td>
</tr>
<tr>
<td>1-hexadecanoylhexahydro-1H-azepine</td>
<td>63%</td>
<td>205 / 0.5 mm</td>
</tr>
</tbody>
</table>

Example 4

Preparation of 1-dodecanoylhexahydro-1H-azepine

A mixture of dodecanoic acid (20.03 g, 0.1M), acetic anhydride (13.27 g, 0.13M), hexahydro-1H-azepine (12.9 g, 0.13M) was heated with distillation of formed
acetic acid. The residue on distillation gave 23.46 g (83.5%) of colorless product, b.p. 204-205 / 7 mm.

The following compounds were prepared analogously by substituting equimolar amount of the corresponding carboxylic acids:

- 1-butyrylhexahydro-1H-azepine 63.2% 133-4 / 11 mm
- 1-pentanoylhexahydro-1H-azepine 84% 141-2 / 7 mm
- 1-decanoylhexahydro-1H-azepine 81% 181-3 / 6 mm

**Example 5**

Preparation of 1-butyryl-2-carboxypyrrolidine (1-butyryl-L-proline)

11.4 m. (0.11M) of butyryl chloride and 20 ml of 7M NaOH (0.1M) were added in small portions into a chilled solution of L-proline (11.5 g, 0.1M) dissolved in 14.3 ml 7M NaOH (0.1M) according to the method of Kikuchi et. al., Biochim. Biophys. Acta 744,180 (1983). The reaction mixture was stirred vigorously during the addition and was always kept slightly alkaline. After the addition was over the reaction mixture was further stirred for an hour at 0-5 C. The mixture was then extracted with one portion of ethyl acetate and the aqueous layer was acidified with HCl to pH 1.8. The precipitated product was washed with cold water and dried in vacuo. Recrystallization from acetone gave 14 g (82%) of the product.

The following compounds were similarly prepared by substituting equimolar amounts of the corresponding carboxylic acid chlorides:

- 1-hexanoyl-2-carboxypyrrolidine (1-hexanoyl-L-proline)
- 1-octanoyl-2-carboxypyrrolidine (1-octanoyl-L-proline)
- 1-decanoyl-2-carboxypyrrolidine (1-decanoyl-L-proline)
- 1-dodecanoyl-2-carboxypyrrolidine (1-dodecanoyl-L-proline)
- 1-tetradecanoyl-2-carboxypyrrolidine (1-tetradecanoyl-L-proline)
- 1-hexadecanoyl-2-carboxypyrrolidine (1-hexadecanoyl-L-proline)
Example 6

The general procedure of Example 5 is repeated, except that the L-proline utilized therein is replaced, successively, with an equimolar amount of 2-piperidinecarboxylic acid and butyryl chloride is replaced, successively, with an equimolar amount of C6, C8, C10, C12, C14 and C16 carboxylic acid chlorides to produce, respectively
l-hexanoyl-2-carboxypiperidine
l-octanoyl-2-carboxypiperidine
l-decanoyl-2-carboxypiperidine
l-dodecanoyl-2-carboxypiperidine
l-tetradecanoyl-2-carboxypiperidine
l-hexadecanoyl-2-carboxypiperidine

Example 7

The general procedure of Example 5 is repeated, except that L-proline utilized therein is replaced, successively, with an equimolar amount of 3-piperidinecarboxylic acid and butyryl chloride is replaced, successively, with an equimolar amount of C6, C8, C10, C12, C14 and C16 carboxylic acid chlorides to produce, respectively
l-hexanoyl-3-carboxypiperidine
l-octanoyl-3-carboxypiperidine
l-decanoyl-3-carboxypiperidine
l-dodecanoyl-3-carboxypiperidine
l-tetradecanoyl-3-carboxypiperidine
l-hexadecanoyl-3-carboxypiperidine

Example 8

The general procedure of Example 5 is repeated, except that L-proline utilized therein is replaced, successively, with an equimolar amount of 4-piperidinecarboxylic acid and butyryl chloride is replaced, successively, with an equimolar amount of C6, C8, C10, C12, C14 and C16 carboxylic acid chlorides to produce, respectively
1-hexanoyl-4-carboxypiperidine
1-octanoyl-4-carboxypiperidine
1-decanoyl-4-carboxypiperidine
1-dodecanoyl-4-carboxypiperidine
1-tetradecanoyl-4-carboxypiperidine
1-hexadecanoyl-4-carboxypiperidine

**Example 9**

The following solution formulation is prepared:

<table>
<thead>
<tr>
<th>Solution%</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
</tr>
<tr>
<td>1</td>
</tr>
<tr>
<td>5</td>
</tr>
<tr>
<td>0.1</td>
</tr>
<tr>
<td>92.9</td>
</tr>
</tbody>
</table>

This formulation is effective in the treatment of fungus infections.

**Example 10**

An aerosol form of the formulation of Example 10 is prepared by preparing the following mixture:

<table>
<thead>
<tr>
<th>Formulation 25%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Freon 75%</td>
</tr>
</tbody>
</table>

Freon is 75/25 Freon 114/12

**Example 11**

The following cream formulation is prepared:

<table>
<thead>
<tr>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clindamycin base 1.0</td>
</tr>
<tr>
<td>Stearyl alcohol, U.S.P. 12.0</td>
</tr>
<tr>
<td>Ethoxylated cholesterol 0.4</td>
</tr>
<tr>
<td>Synthetic spermacte 7.5</td>
</tr>
<tr>
<td>Sorbitan monoooleate 1.0</td>
</tr>
<tr>
<td>Polysorbate 80, U.S.P. 3.0</td>
</tr>
<tr>
<td>1-dodecanoylhexahydro-1H-azepine 0.5</td>
</tr>
<tr>
<td>Sorbitol solution, U.S.P. 5.5</td>
</tr>
<tr>
<td>Sodium citrate 0.5</td>
</tr>
<tr>
<td>Chemoderm #844 Fragrance 0.2</td>
</tr>
</tbody>
</table>
Purified water 68.4

This formulation is effective in the treatment of acne.

Example 12

The following solution formulations are prepared:

<table>
<thead>
<tr>
<th></th>
<th>A (%)</th>
<th>B (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clindamycin base</td>
<td>-</td>
<td>1.0</td>
</tr>
<tr>
<td>Clindamycin phosphate acid</td>
<td>1.3</td>
<td>-</td>
</tr>
<tr>
<td>Sodium hydroxide</td>
<td>0.077-</td>
<td>-</td>
</tr>
<tr>
<td>1M Hydrochloric acid</td>
<td>-</td>
<td>2.27</td>
</tr>
<tr>
<td>Disodium edetate. 2H2O</td>
<td>0.003</td>
<td>0.003</td>
</tr>
<tr>
<td>Fragrances</td>
<td>0.5</td>
<td>0.5</td>
</tr>
<tr>
<td>1-dodecanoylhexahydro-1H-azepine</td>
<td>1.0</td>
<td>1.0</td>
</tr>
<tr>
<td>Purified water</td>
<td>20.0</td>
<td>17.73</td>
</tr>
<tr>
<td>Isopropanol</td>
<td>77.12</td>
<td>77.497</td>
</tr>
</tbody>
</table>

These solutions are effective for the treatment of acne in humans.

Example 13

The following solution formulation is prepared:

%  
Neomycin sulfate 0.5  
Lidocaine 0.5  
Hydrocortisone 0.25  
1-dodecanoylhexahydro-1H-azepine 0.5  
Propylene glycol 98.25  

This solution is effective for the treatment of otitis in domestic animals.

Example 14

The following sunscreen emulsion is prepared:

%  
p-aminobenzoic acid 2.0  
Benzyl alcohol 0.5  
1-dodecanoylhexahydro-1H-azepine 1.0  
Polyethylene glycol 500-MS 10.0  
Isopropyl lanolate 3.0
Example 15

The following antineoplastic solution is prepared:

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>5-fluorouracil</td>
<td>5</td>
</tr>
<tr>
<td>1-dodecanoylhexahydro-1H-azepine</td>
<td>0.1</td>
</tr>
</tbody>
</table>

Example 16

The following insect repellent atomizing spray is prepared:

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>N,N-diethyltoluamide</td>
<td>0.5</td>
</tr>
<tr>
<td>1-dodecanoylhexahydro-1H-azepine</td>
<td>0.5</td>
</tr>
<tr>
<td>Ethanol</td>
<td>99</td>
</tr>
</tbody>
</table>

Example 17

The following cream formulation may be prepared containing about 0.001 to 1 percent, with preferably 0.1 percent fluocinolone acetonide:

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oil phase</td>
<td></td>
</tr>
<tr>
<td>Fluocinolone acetonide</td>
<td>0.1</td>
</tr>
<tr>
<td>1-dodecanoylhexahydro-1H-azepine</td>
<td>1</td>
</tr>
<tr>
<td>Cetyl alcohol</td>
<td>9.5</td>
</tr>
<tr>
<td>Stearyl alcohol</td>
<td>1.5</td>
</tr>
<tr>
<td>Glyceryl monostearate</td>
<td>4</td>
</tr>
</tbody>
</table>
Water phase
Propylene glycol 10
Sodium dodecyl sulfate 0.1
Deionized water q.s. 100

The steroid is dissolved in the vehicle and added to a stirred, cooling melt of the other ingredients. The preparation is particularly useful for the treatment of inflamed dermatoses by topical application to the affected skin area. The amount of frequency of application of this steroid. Penetration of the steroid in the inflamed tissue is enhanced and a therapeutic level is achieved more rapidly and sustained for longer duration than when the steroid is applied in conventional formulation.

Example 18

The following analgesic gel is prepared:

\[
\begin{align*}
\text{%} & \\
\text{Carbopol 934} & 1 \\
\text{Indomethacin} & 1 \\
\text{Propylene glycol} & 20 \\
\text{Ethanol} & 10 \\
\text{Diisopropanolamine} & 30 \\
\text{Diisopropyl adipate} & 1.1 \\
\text{1-dodecylhexahydro-1H-azepine} & 2 \\
\text{Water} & 52.9
\end{align*}
\]

Example 19

The following cream formulation is prepared:

\[
\begin{align*}
\text{%} & \\
\text{Isosorbide dinitrate} & 10 \\
\text{Glycerol monostearate} & 30 \\
\text{Polyoxyethylene stearate} & 5.5 \\
\text{C8-C18 fatty acid esters of a glycerol ethoxylated with about 7 moles of ethylene oxide} & 4.5 \\
\text{8} & 8 \\
\text{1-dodecanoylhexahydro-1H-azepine} & 2 \\
\text{Sorbic acid} & 35 \\
\text{Ascorbyl palmitate} & 0.165 \\
\text{0.055}
\end{align*}
\]
This formulation is effective in the treatment of angina.

**Example 20**

The following skin moisturizing formulation is prepared:

- **Pyrrolidonecarboxylic acid Na**: 1%
- **Glycerine**: 4%
- **Citric acid**: 0.03%
- **Sodium citrate**: 0.05%
- **Allantoin**: 0.1%
- **Ethanol, 95%**: 9%
- **Oleth-15**: 1%
- **Linoleic acid**: 1%
- **1-dodecanoyl-L-proline**: 2%
- **Sunscreen agent**: 0.1%
- **Water**: 81.72%
In addition to the above exemplified applications of the compositions and methods, the invention finds significant application in agricultural and other biological fields. For example, the compositions and methods of the invention are useful in enhancing the penetration of hybridization agents. Agents of this type are described in the literature. For example, the compositions of the present invention carrying pollen suppressant agents such as the substituted dihydropyridazines described by Fang and Labovitz, U.S. Patent No. 4,561,881, in the concentration ranges shown in the examples above may be used to enhance the penetration and effectiveness of these agents.

Nitroarylalkylsulfone derivatives, as described by Fankhauser and Sturm, U.S. Patent No. 4,459,152, in a concentration of from about 0.01 to 1 percent may be applied as a growth stimulant to plants and seeds. Biochemical and biological agents for enhancing, diminishing or terminating plant growth, for enhancing, diminishing or terminating fertility of plants, seeds, pollen and the like in solutions of the described compositions are highly advantageous in agricultural research and production. Other agricultural applications include compositions comprising the enhancing of absorption of therapeutic and other livestock treating compositions.

**Industrial Application**

This invention finds application in the health care, pharmaceutical, animal husbandry and agricultural applications to enhance the penetration or absorption of biologically active agents.
WHAT IS CLAIMED IS:

1. A composition useful for topically administering physiologically active agents through the skin and mucous membranes of humans and animals in a transdermal device or formulation for systemic use or to the skin of humans and animals for localized use comprising an effective amount of a physiologically active agent and a non-toxic, effective penetrating amount of a compound having the structural formula

\[
(CH_2)_m - N-C-R
\]

\[
\text{(R')}n
\]

where \( R \) is an alkyl group with 1 to 19 carbon atoms, \( m \) is 4, 5 or 6, \( R' \) is \( H \) and COOH and \( n \) is 0 to 4.

2. The composition of Claim 1 wherein the physiologically active agent is an antibacterial agent.

3. The composition of Claim 1 wherein the antibacterial agent is an antibiotic.

4. The composition of Claim 1 wherein the antibiotic is selected from the group consisting of lincomycin, clindamycin, erythromycin and pharmaceutically useful salts thereof.

5. The composition of Claim 1 wherein the physiologically active agent is physiologically active steroid.

6. The composition of Claim 1 wherein the physiologically active agent is an antifungal agent.

7. The composition of Claims 1 wherein the physiologically active agent is iododeoxyuridine.

8. The composition of Claim 1 wherein the physiologically active agent is 5-fluorouracil.

9. The composition of Claim 1 wherein the physiologically active agent is an
-24-

anti-inflammatory/analgesic agent.

10. The composition of Claim 9 wherein the anti-inflammatory/analgesic active agent is selected from the group consisting of indomethacine, diclofenac, ketoprofen, ibuprofen, fenamic acids and pharmaceutically acceptable salts thereof.

11. The composition of Claim 1 wherein the physiologically active agent is bronchodilator or metaproterenol.

12. The composition of Claim 1 wherein the physiologically active agent is an antipruritic agent.

13. The composition of Claim 1 wherein the physiologically active agent is clonidine.

14. The composition of Claim 1 wherein the physiologically active agent is a neuroleptic.

15. The composition of Claim 1 wherein the physiologically active agent is a vasodilator.

16. The composition of Claim 15 wherein the vasodilator is selected from the group consisting of nitroglycerine, isosorbide dinitrate and pentaerythritol tetranitrate.

17. A composition comprising an effective amount of a physiologically active agent and an effective penetrating amount of a compound having the structural formula:

\[
\begin{align*}
\text{(CH}_2\text{)}_m \quad & \quad \text{O} \\
\text{N-C-R} \\
\text{(R')}_n
\end{align*}
\]

30 where, R is an alkyl group with 4 to 19 carbon atoms, where, m is 4 to 6, R' is H and COOH and n is 0 to 4.

18. A composition comprising an effective amount of a physiologically active agent and an effective, penetrating amount of 1-dodecanoylhexahydro-1H-azepine.

19. A composition comprising an effective amount of a physiologically active agent and an effective,
penetrating amount of 1-dodecanoyl-2-carboxyprrolidine.

20. A composition comprising an effective amount of a physiologically active agent and an effective, penetrating amount of 1-dodecanoyl-2-carboxypiperidine.

21. A method for topical administration of systemically active agents through the skin or mucosal membranes of humans and animals in a transdermal device or formulation, the improvement comprising the topical administration of an effective amount of a membrane penetration enhancer having the structural formula,

$\text{(CH}_2\text{)}_m \overset{O}{\text{N-C-R}} \text{R''}$

where, m is an alkyl group with 1 to 19 carbon atoms; R is H, n is 0, and m is 4 to 6.

22. The method of Claim 21 wherein R is 6 to 19.
23. The method of Claim 21 wherein m is 6.
24. The method of Claim 23 wherein R is 6 to 19.
25. The method of Claim 21 wherein the penetration enhancer is 1-dodecanoylhexahydro-1H-azepine.
26. The method of Claim 21 wherein m is 4.
27. The method of Claim 26 wherein R' is COOH.
28. The method of Claim 26 wherein n is 1.
29. The method of Claim 26 wherein R is 6 to 19.
30. The method of Claim 21 wherein the penetration enhancer is 1-dodecanoyl-2-carboxyprrolidine.
31. The method of Claim 21 wherein the penetration enhancer is 1-dodecanoyl-2-carboxypiperidine.
32. The method of Claim 21 wherein the systemically active agent is a therapeutic agent.
33. The method of Claim 34 wherein the administration is concurrent.
34. A composition comprising a physiologically acceptable carrier and an amount of 1-dodecanyl-2-carboxyprrolidine effective to moisturize the skin to which such composition may be applied.
**INTERNATIONAL SEARCH REPORT**

**International Application No.** PCT/US86/02052

**I. CLASSIFICATION OF SUBJECT MATTER**

If several classification symbols apply, indicate all.

- US Cl. 514/844, 847, 873, 946, 947, 969 604/896, 897
- IPC A61K 7/48 A61K 47/00 A61L 15/03

**II. FIELDS SEARCHED**

Minimum Documentation Searched:

<table>
<thead>
<tr>
<th>Classification System</th>
<th>Classification Symbols</th>
</tr>
</thead>
<tbody>
<tr>
<td>U.S.</td>
<td>514/844, 847, 873, 946, 947, 969</td>
</tr>
<tr>
<td></td>
<td>604/896, 897</td>
</tr>
</tbody>
</table>

Documentation Searched other than Minimum Documentation to the extent that such Documents are included in the Fields Searched:

- RAIJADHYAKSHA, VITHAL J.

**III. DOCUMENTS CONSIDERED TO BE RELEVANT**

<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of Document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to Claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>U.S.A, 3,711,606 (HERSCHLER) issued 16 January 1973, see entire document.</td>
<td>1 to 34</td>
</tr>
<tr>
<td>A</td>
<td>U.S.A, 3,742,951 (ZAFFARONI) issued 03 July 1973, see entire document.</td>
<td>1 to 34</td>
</tr>
<tr>
<td>A</td>
<td>U.S.A, 3,989,815 (RAIJADHYAKSHA) issued 02 November 1976, see entire document.</td>
<td>1 to 34</td>
</tr>
<tr>
<td>A</td>
<td>U.S.A, 3,989,816 (RAIJADHYAKSHA) issued 02 November 1976, see entire document.</td>
<td>1 to 34</td>
</tr>
<tr>
<td>A</td>
<td>U.S.A, 3,991,203 (RAIJADHYAKSHA) issued 09 November 1976, see entire document.</td>
<td>1 to 34</td>
</tr>
<tr>
<td>A</td>
<td>U.S.A, 3,996,934 (ZAFFARONI) issued 14 December 1976, see entire document.</td>
<td>1 to 34</td>
</tr>
</tbody>
</table>

* Special categories of cited documents:
- "A" document defining the general state of the art which is not considered to be of particular relevance.
- "E" earlier document but published on or before the international filing date.
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified).
- "O" document referring to an oral disclosure, use, exhibition or other means.
- "P" document published prior to the international filing date but later than the priority date claimed.
- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention.
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step.
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "S" document of the same patent family.

**IV. CERTIFICATION**

Date of the Actual Completion of the International Search: 02 December 1986

Date of Mailing of this International Search Report: 08 DEC 1986

Signature of Authorized Officer: Shap K. Rose

International Searching Authority: ISA/US
<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of Document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to Claim No</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>U.S.A, 4,415,563 (RAJADHYAKSHA) issued 15 November 1983, see entire document.</td>
<td>1 to 34</td>
</tr>
<tr>
<td>A</td>
<td>U.S.A, 4,423,040 (RAJADHYAKSHA) issued 27 December 1983, see entire document.</td>
<td>1 to 34</td>
</tr>
<tr>
<td>A</td>
<td>U.S.A, 4,424,210 (RAJADHYAKSHA) issued 03 January 1984, see entire document.</td>
<td>1 to 34</td>
</tr>
<tr>
<td>A</td>
<td>U.S.A, 4,444,762 (RAJADHYAKSHA) issued 24 April 1984, see entire document.</td>
<td>1 to 34</td>
</tr>
<tr>
<td>A</td>
<td>U.S.A, 4,461,638 (RAJADHYAKSHA) issued 24 July 1984, see entire document.</td>
<td>1 to 34</td>
</tr>
<tr>
<td>A</td>
<td>U.S.A, 4,525,199 (RAJADHYAKSHA) issued 25 June 1985, see entire document.</td>
<td>1 to 34</td>
</tr>
<tr>
<td>A</td>
<td>U.S.A, 4,557,934 (COOPER) issued 10 December 1985, see entire document.</td>
<td>1 to 34</td>
</tr>
<tr>
<td>A</td>
<td>U.S.A, 4,562,075 (RAJADHYAKSHA) issued 31 December 1985, see entire document.</td>
<td>1 to 34</td>
</tr>
<tr>
<td>A</td>
<td>U.S.A, 4,568,343 (LEEPEER ET AL) issued 04 February 1986, see entire document.</td>
<td>1 to 34</td>
</tr>
<tr>
<td>A</td>
<td>U.S.A, 5,573,996 (KWIAK ET AL) issued 04 March 1986, see entire document.</td>
<td>1 to 34</td>
</tr>
</tbody>
</table>
FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>A</strong></td>
<td>U.S.A, 4,122,170 (RAJADHYAKSHA) issued 24 October 1978, see entire document.</td>
</tr>
<tr>
<td><strong>A</strong></td>
<td>U.S.A, 4,316,893 (RAJADHYAKSHA) issued 23 February 1982, see entire document.</td>
</tr>
<tr>
<td><strong>A</strong></td>
<td>U.S.A, 4,405,616 (RAJADHYAKSHA) issued 20 September 1983, see entire document.</td>
</tr>
<tr>
<td></td>
<td>1 to 34</td>
</tr>
</tbody>
</table>

**V. OBSERVATIONS WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE**

This international search report has not been established in respect of certain claims under Article 17(2) (a) for the following reasons:

1. Claim numbers ........ , because they relate to subject matter required not to be searched by this Authority, namely:

2. Claim numbers ........ , because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

**VI. OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING**

This International Searching Authority found multiple inventions in this international application as follows:

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims of the International application.
2. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims of the International application for which fees were paid, specifically claims:
3. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claim numbers:
4. As all searchable claims could be searched without effort justifying an additional fee, the International Searching Authority did not invite payment of any additional fee.

Remark on Protest
- The additional search fees were accompanied by applicant’s protest.
- No protest accompanied the payment of additional search fees.

Form PCT/ISA/210 (supplemental sheet (2) [May 1986]